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Nasopharyngeal carcinoma (NPC) is a highly aggressive tumor characterized by distant metastasis. 32 
Deletion or down-regulation of the tumor suppressor protein ras-association domain family 33 
protein1 isoform A (RASSF1A) has been confirmed to be a key event in NPC progression; 34 
however, little is known about the effects or underlying mechanism of RASSF1A on the 35 
malignant phenotype. In the present study, we observed that RASSF1A expression inhibited the 36 
malignant phenotypes of NPC cells. Stable silencing of RASSF1A in NPC cell lines induced 37 
self-renewal properties and tumorigenicity in vivo/in vitro and the acquisition of an invasive 38 
phenotype in vitro. Mechanistically, RASSF1A inactivated Yes-associated Protein 1 (YAP1), a 39 
transcriptional coactivator, through actin remodeling, which further contributed to Platelet Derived 40 
Growth Factor Subunit B (PDGFB) transcription inhibition. Treatment with ectopic PDGFB 41 
partially reversed the malignant phenotypes of NPC cells with transient knockdown of YAP1. 42 
Collectively, these findings suggest that RASSF1A inhibits malignant phenotypes by repressing 43 
PDGFB expression in a YAP1-dependent manner. PDGFB may serve as a potential interest of 44 
therapeutic regulators in patients with metastatic NPC. 45 
1. Introduction 46 
Ras-association domain family protein1 isoform A (RASSF1A) is a well-known tumor suppressor 47 
protein inactivated by a combination of genetic and epigenetic mechanisms in various human 48 
cancers. RASSF1A is located on chromosome 3p21.3 and is downregulated in human tumor cells 49 
most frequently by promoter methylation and infrequently by mutation or deletion1. RASSF1A 50 
contains a ras association domain, an ataxia telangiectasia mutant (ATM) kinase phosphorylation 51 
site, and Sav-RASSF-Hpo (SARAH) protein interaction domain in C-terminus, and its N-terminal 52 
sequence contains a diacyl glycerol binding domain 2-4. RASSF1A lacks obvious enzymatic 53 
activity but may serve as a scaffold protein for signaling complexes by binding to key signaling 54 
mediators. The SARAH domain is a key feature of Hippo signaling pathway components, and the 55 
interaction of Sav, Rassf, and Hippo is accomplished via this domain. The Hippo pathway is a 56 
kinase cascade connecting the tumor suppressor Hippo (Mst1 and Mst2 in mammals) to the Yki 57 
protein (YAP1(Yes-associated protein 1) and TAZ (Tafazzin) in mammals), a transcriptional 58 
coactivator of target genes involved in cell proliferation, cell cycle regulation and apoptosis5,6. 59 
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RASSF1A interacts with Mst1/2 via its SARAH domain and promotes the formation of an 60 
inhibitory complex comprising RAF1 and MST1/2, which then inhibits Lats1 phosphorylation and 61 
retains inactivated YAP1 in the cytoplasm7. It was also demonstrated that RASSF1A positively 62 
regulating Mst1 apoptotic activity, further leading to histone H2B phosphorylation, a hallmark of 63 
chromatin condensation8. The key upstream repressor of YAP1/TAZ activation is the Hippo 64 
(MST1/2-LATS1/2) pathway and apart from it, YAP1/TAZ could be mechanically activated by 65 
Integrin, PI3K-AKT and G-protein coupled receptor (GPCR) signals, all of which antagonize the 66 
Hippo pathway9. Accumulating studies have reported that RASSF1A triggers tyrosine 67 
phosphorylation of YAP1 and modulates its activation during various processes, including injury, 68 
inflammation and carcinogenesis10. Overexpression of RASSF1A significantly inhibits cell 69 
proliferation and induces apoptosis by inhibiting the oncogenic functions of YAP111. Acting as a 70 
downstream effector of the Hippo pathway, YAP1 has been identified as a proto-oncogene, as 71 
it acts by binding to the transcription factor TEAD1-4 (TEA domain family member , the major 72 
partner of YAP1 in its function in the Hippo pathway) and subsequently activates the transcription 73 
of genes involved in cell survival/proliferation and suppresses the transcription of apoptotic genes 74 
such as c-Myc, OCT4, CYR61 and CTGF 12-14.  75 
Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in South China and 76 
Southeast Asia. NPC has the highest metastasis rate among head and neck cancers, and patients 77 
with distant metastasis experience higher rates of treatment failure15,16. Cancer stem cells (CSCs) 78 
are a small subpopulation of cells residing in tumors. CSCs of NPC have self-renewal, 79 
differentiation, and tumorigenic capabilities and are considered the cause of therapeutic resistance, 80 
tumor recurrence and metastasis17-19. Variable expression of HIPPO-TAZ regulated by cisplatin 81 
treatment20 or by EBV-LMP121 in NPC cells contributes to cancer stem cell-like properties and 82 
epithelial-mesenchymal transition. A high frequency of RASSF1A inactivation or down-regulation 83 
by gene promoter hypermethylation has been observed in NPC22,23. RASSF1A impairs cell 84 
proliferation in vitro and in vivo24, and methylation of its promoter has been linked to unfavorable 85 
prognosis in patients with NPC25,26. Restoration of RASSF1A expression is difficult due to 86 
technical issues and is accompanied by unpredictable complications; thus, determining its 87 
downstream effectors is necessary.  88 
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In the present study, we demonstrated that RASSF1A impairs malignant phenotypes by 89 
inhibiting YAP1-mediated expression of PDGFB during multiple steps of NPC carcinogenesis. 90 
2. Materials and Methods 91 
2.1 Cell culture, reagents and ELISAs 92 
Well-differentiated CNE-1, poorly differentiated CNE-2 and SUNE-1 are commonly used NPC 93 
cell lines in scientific research. All of them were maintained in DMEM (Invitrogen, USA) 94 
supplemented with 10% fetal bovine serum (FBS; Invitrogen, USA) at 37°C and 5% CO2. Cells 95 
were plated in 6-well plates (Corning, USA) and treated with humane recombinant PDGF-BB 96 
(220-BB-010, R&D Systems, USA) or Immunoglobulin G (IgG) control (AB-108-C, R&D 97 
Systems, USA) or neutralizing antibody against PDGF-BB(AB-220-NA, R&D Systems, USA) or 98 
latrunculin b (LTB, ab144291, Abcam, UK) twelve hours after plating. The PDGF-BB level in 99 
supernatant of cultured cell was measured using ELISA Kits for PDGF-BB (DBB00, R&D 100 
Systems, USA) according to the manufacturer's instructions. 101 
2.2 Cell proliferation assay and Spheroid formation assay 102 
To plot the cellular growth curve, 1×103 cells suspended in 200μl of medium were seeded into a 103 
96-well plate (Corning, USA) and cultured under normal conditions. At various time points after 104 
seeding, the cells in each well were stained with MTS (G5421, Promega, USA), and the OD490 105 
was determined with a microplate reader. Single-cell suspensions containing 800-1000 cells were 106 
seeded in 12-well ultra-low-attachment culture plates (Corning, USA) and cultured in serum-free 107 
DMEM/F12 (11320082, Invitrogen, USA)supplemented with 20 ng/ml EGF (PHG0311, 108 
Invitrogen, USA) and 10 ng/ml bFGF (PHG0360, Invitrogen, USA) for 10-14 days. The formed 109 
spheroids were counted and representative images were acquired via microscopy.  110 
2.3 Plasmid construction and transfection 111 
A RASSF1 expression construct was generated by subcloning PCR amplified full-length human 112 
RASSF1 (transcript variant A) cDNA into a plasmid. Cells stably expressing either RASSF1A 113 
short hairpin RNA (shRNA) targeting RASSF1 (transcript variant A) or a scrambled, non targeting 114 
shRNA were generated using the LV3 plasmid according to the manufacturer’s instructions. The 115 
target sequences of RASSF1A shRNA-2 and shRNA-5 were 116 
5'-CGTGGACGAGCCTGTGGAG-3' and 5'-GCTGAGATTGAGCAGAAGA-3', respectively. 117 
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Retroviral production and infection were performed as previously described27, and stable cell lines 118 
were selected using 1-3 mg/ml puromycin for 5-7 days. 119 
2.4 Small interfering RNA (siRNA) transfection 120 
The siRNA mixed sequences targeting YAP1 (L-012200-00-0005) and PDGFB 121 
(L-011749-00-0005) were purchased from Dharmacon (USA). A non-targeting siRNA sequence 122 
(D-001210-01-05, Dharmacon, USA) was used as negative control. Cells (2×105 cells per well) 123 
were seeded in a 6-well tissue culture dish, and the siRNAs (50 nM) were added twenty-four 124 
hours later using RNAiMAX reagent (13778-075, Invitrogen, USA).The transfected cells were 125 
incubated for 6 hours and were then supplied with fresh medium containing serum. 126 
2.5 Transwell assay 127 
Migration and invasion assays were performed using cell culture inserts with transparent 128 
polyethylene terephthalate filters with an 8-μm pore size (354480, Corning, USA) with (for 129 
invasion assays) or without (for migration assays) matrigel coating. CNE-2 cells (2 × 104) and 130 
CNE-1cells (5 × 104) suspended in 200μl of serum-free DMEM with or without 12h pretreatment 131 
with mitomycin C (1ug/ml), then were added to the upper chambers, and 800μl of DMEM 132 
containing 10% FBS was added to the bottom chambers. After incubation for twenty hours at 133 
37 °C, the cells on the upper filter were removed, and the cells that invaded the membrane or 134 
migrated to its lower surface were fixed with methanol and stained with crystal violet. Three 135 
optical fields were randomly selected from each of three inserts to calculate the average numbers 136 
of migrated or invaded cells. 137 
2.6 Immunofluorescence analysis 138 
Cells were blocked for thirty minutes in 5% BSA and incubated with phalloidin (A12379, 139 
Invitrogen, USA) at a 1:100 dilution for 1 hour in the dark at room temperature. Then, slides were 140 
stained with DAPI (D1306, Invitrogen, USA) for 5 min to visualize nuclei. Images were acquired 141 
via high-throughput confocal microscopy. 142 
2.7 Western blot analysis 143 
Nuclear and cytosolic fractionation was performed using a subcellular protein fractionation 144 
kit (78840, Invitrogen, USA). Immunoblotting was performed according to standard methods 145 
as described previously28. Primary antibodies against the following proteins were used at a 146 
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concentration of 1:1000: RASSF1A(ab97749) from Abcam (UK) and YAP1(#14074), 147 
α-tubulin (#3873), Histone-H3(#4499), E-cadherin(#3195), Vimentin(#5741), β-actin 148 
(#4970), and GAPDH(#2118) from Cell Signaling Technology (USA). 149 
2.8 Real-time reverse transcription-quantitative PCR (qRT-PCR) 150 
The mRNA levels of YAP1, PDGFB, Cysteine-rich angiogenic inducer 61(CYR61) and connective 151 
tissue growth factor (CTGF) were measured by real-time qRT-PCR according to the 152 
manufacturer’s instructions27. The house keeping gene GAPDH was used as the internal 153 
normalization control to calculate the mRNA levels of the different genes.  154 
2.9 In vivo tumorigenicity experiments 155 
The protocol for the xenograft experiments was approved by the Institutional Animal Care and 156 
Use Committee of Sun Yat-Sen University Cancer Center. Female BALB/c nude mice (4-6 weeks 157 
old, 15-18 g; Animal Center of Guangdong Province) were housed in barrier facilities. The 158 
indicated tumor cells (5×104 or 2×105) were suspended in 100μl of sterile PBS containing 50% 159 
matrigel (356243, BD Biosciences, USA) and were subcutaneously inoculated into the mice (n=10 160 
per group). The mice were monitored daily for palpable tumor formation. All mice were 161 
euthanized 5 weeks after injection. The tumor-initiating cell frequency (TIF) was calculated using 162 
extreme limiting dilution analysis (ELDA) software (http://bioinf.wehi.edu.au/software/elda/). 163 
2.10 Genome-wide expression profiling, pathway analysis 164 
Genome-wide expression profiling of RASSF1A-overexpressing CNE-2 and RASSF1A-depleted 165 
CNE-1cells and their corresponding control vector cells was performed by Sagene Biotech Co. 166 
(Guangzhou, China). Raw data were normalized by log2 transformation and z-score calculation 167 
[(individual log transformed signal intensity (LS) value- mean of all LS values)/ S.D. of all LS 168 
values]. Normalized data were used for statistical analyses.  169 
2.11 Statistics 170 
All statistical analyses were carried out using SPSS 19.0 (IBM, Chicago, IL, USA). The data are 171 
presented as the means ± standard errors (SEs) of at least three independent experiments. 172 
Two-tailed Student's t-test was used to compare data between two groups. For all cell culture 173 
experiments, technical triplicates were evaluated in at least three independent experiments. P 174 
values of< 0.05 were considered statistically significant. 175 
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3. Results 176 
3.1 RASSF1A suppresses self-renewal properties and tumorigenicities of NPC cells 177 
We evaluated RASSF1A expression in commonly used NPC cell lines and found that CNE-1 cells, 178 
which exhibits a well differentiated phenotype, had higher levels of RASSF1A, whereas 179 
poor-differentiated CNE-2 had lowest level of RASSF1A(Fig. 1A). To determine whether 180 
RASSF1A plays oncogenic roles in NPC cells, we infected CNE-2 NPC cells with wild-type 181 
RASSF1A- or empty control vector-expressing lentivirus (Fig. 1B, left panel). Significantly fewer 182 
CNE-2 cells transfected with RASSF1A were observed in the proliferation assay (Fig.1C). In 183 
addition, the RASSF1A-overexpressing CNE-2 NPC cells formed smaller and fewer spheres than 184 
the empty vector-transfected cells (Fig.1D).  185 
To determine whether NPC cells with RASSF1A overexpression can exhibit tumorigenicity in 186 
vivo, we injected CNE-2 cells with RASSF1A- or empty vector-expressing lentivirus at different 187 
inoculation densities into nude mice. The TIF (tumor-initiating cell frequency) significantly 188 
reduced in RASSF1A-overexpressing CNE2 cells compared with control cells (Fig.1G and Fig. 189 
S1). 190 
We subsequently studied whether depletion of RASSF1A is sufficient to confer self-renewal 191 
properties. CNE-1 cell lines with high levels of RASSF1A expression were selected for 192 
loss-of-function assays. We knocked down RASSF1A in CNE-1 NPC cells and confirmed the 193 
reduced expression of RASSF1A by western blot analysis (Fig.1B, right panel).RASSF1A 194 
knockdown increased the number of viable CNE-1 cells (Fig.1E) and their anchorage independent 195 
growth, as these cells formed more and larger spheres than those transduced with scrambled 196 
shRNA (Fig.1F). To rule out the off target effect of shRNA, we re-expressed RASSF1A in 197 
RASSF1A-knockdown CNE-1 cells with silent mutation in shRNA target region for conferring 198 
resistance. Restoration of RASSF1A significantly reduced the accelerated ability of proliferation 199 
and sphere formation leaded by RASSF1A-knockdown in CNE-1 cells (Fig.S2A-C). ShRNA 200 
targeting region also matched other transcript variant of RASSF1. RASSF1D isoform was at 201 
undetectable mRNA level in CNE-1 cells (data not shown), we therefore re-expressed RASSF1B 202 
in CNE-1/sh2 cells and re-expressed shRNA-resistant RASSF1C in CEN-1/sh5 cells and observed 203 
cell growth. There was no significant changed of phenotype (Fig.S2D-E), which was inconsistent 204 
with literature reported that RASSF1C plays oncogenic function. It may probably due to CNE-1 205 
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cells had relatively low intrinsic expression of RASSF1C. 206 
Next we injected shRNA-mediated RASSF1A-knockdown CNE-1 cells and control cells at 207 
different inoculation densities into NOD/SCID mice, control CNE-1 cells failed to form tumors in 208 
nude mice after the full observation period. However, the RASSF1A-silenced CEN-1 cells showed 209 
increased TIF (Fig.1H and Fig.S1). 210 
3.2 RASSF1A regulated expression of markers involved in cell movement and ultimately 211 
inhibits the invasive phenotype of NPC cells 212 
The above results suggest that RASSF1A depletion induces a CSC characteristic. CSCs are 213 
responsible for increased motility and the invasive phenotype of cancer cells. Thus, we evaluated 214 
the expression of molecules involved in the process of cell-cell adhesion and cell movement in 215 
NPC cell lines29,30. RASSF1A-overexpressing CNE-2 cells showed increased E-cadherin 216 
expression and decreased vimentin expression. In contrast, RASSF1A-depleted CNE-1 cells had 217 
undergone EMT, as indicated by the concomitantly decreased E-cadherin expression and 218 
increased vimentin expression (Fig.2A). Next, we performed cell invasion and migration assays 219 
using Transwell chambers coated with or without an extracellular matrix. Overexpression of 220 
RASSF1A significantly reduced the ability of CNE-2 cells to migrate in the transwell chamber 221 
and invade the extracellular matrix layer. To rule out the influence of cell proliferation, we 222 
repeated the assay of migration and invasion in the presence of mitomycin C, an anti-proliferative 223 
agent, and observed the significant change of migrated and invaded ability of indicated cells 224 
(Fig.2B). We then performed the same experiment and observed the opposite result in CNE-1 cells 225 
with stable knockdown of RASSF1A (Fig.2C). The above data suggested RASSF1Acould inhibit 226 
the motility and invasive phenotype of NPC cells. 227 
3.3 PDGFB induction via RASSF1A deletion is required for the malignant phenotypes of 228 
NPC cells 229 
To reveal the underlying mechanisms by which RASSF1A modulates the stem-like 230 
characteristics of NPC cells, we performed gene expression profiling to compare gene 231 
transcription in RASSF1A-overexpressing, RASSF1A-silenced and control NPC cells. Gene set 232 
enrichment analysis (GSEA) was used to identify a significant association between gene sets 233 
changed by modulation of RASSF1A expression. Then, Kyoto Encyclopedia of Genes and 234 
Genomes (KEGG) pathway analysis was applied to identify key pathways involved in this process. 235 
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In NPC cells, RASSF1A was most significantly involved in the regulation of genes that encode 236 
cytokines (Fig.S3). We used a venn diagram to compare the differentially expressed cytokines and 237 
found that PDGFB expression was significantly changed in both NPC cell lines (Fig.3A). We then 238 
confirmed by using qRT-PCR that the mRNA level of PDGFB was significantly lower in 239 
RASSF1A-overexpressing cells than in empty vector-expressing (control) cells, whereas the 240 
mRNA levels of PDGFB were 2.5-3.5-fold higher in RASSF1A-depleted CNE-1 cells than in 241 
control cells (Fig.3B). PDGFB is released into the microenvironment as a homodimer 242 
(PDGF-BB).To confirm that the changes in PDGFB mRNA expression affected its protein level, 243 
we measured the amount of PDGF-BB secretion in the supernatant of cultured cells. The 244 
PDGF-BB concentration was significantly lower in the supernatant of RASSF1A-overexpressing 245 
cells than in that of their corresponding control cells. In contrast, the PDGF-BB concentration was 246 
higher in the supernatant of RASSF1A- depleted CNE-1 cells than in that of control cells 247 
(Fig.3C). 248 
We next sought to determine whether PDGF-BB secretion controls the acquirement of 249 
malignant phenotypes of NPC cells. PDGFB was transiently silenced in RASSF1A-depleted 250 
CNE-1 cells (Fig.3D). The RASSF1A silencing-induced increase in the number of spheres formed 251 
was partially reduced by PDGFB knockdown or by neutralizing antibody against PDGF-BB 252 
treatment (Fig.3E). Moreover, PDGFB knockdown or neutralizing antibody treatment suppressed 253 
the migration and invasion of RASSF1A-depleted CNE-1 cells (Fig.3F and 3G). 254 
Furthermore, addition of PDGF-BB reversed the malignant phenotypes, including sphere 255 
formation, migration and invasion, of RASSF1A-overexpressing CNE-2 cells (Fig.3H, 3I and 3J). 256 
Collectively, these data suggest that the modulation of malignant NPC cell phenotypes by 257 
RASSF1A is dependent on PDGFB signaling. 258 
3.4 RASSF1A regulates actin cytoskeletal rearrangement and YAP1 activation 259 
The processes of cell motility and adhesion involve the extension and arrangement of 260 
cytoskeleton. The regulation of actin cytoskeleton pathway was also dominantly enriched by 261 
RASSF1A expression (Fig.S3). Although the final cell morphologies were not identical, the cells 262 
were subsequently subjected to F-actin staining. We observed a strikingly anchor-like pattern of 263 
F-actin in RASSF1A-overexpressing cells compared with control cells. Additionally, more F-actin 264 
was arranged along the stretching direction in RASSF1A-depleted cells (Fig.4A). 265 
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The transcriptional coactivator YAP1 has been reported to participate in EMT regulation and 266 
connect with RASSF1A signaling10. Nuclear localization of YAP1 is considered crucial for its 267 
activation. Nuclear YAP1 can bind to DNA-binding transcription factors (including TEAD) to 268 
regulate the expression of target genes. Activation of nuclear YAP1 was significantly inhibited in 269 
RASSF1A-overexpressing CNE-2 cells, as shown by the results of nuclear/cytoplasmic 270 
fractionation assays (Fig.4B) and the concomitant downregulation of CTGF and CYR61, two 271 
well-known YAP1 target genes (Fig.4C). In addition, we observed induced YAP1 nuclear 272 
localization and upregulation of two YAP1 target genes in RASSF1A-depleted CNE-1 cells 273 
(Fig.4B and 4C). Our findings suggest a role for RASSF1A in modulating actin arrangement and 274 
YAP1 activation during NPC development. 275 
3.5 RASSF1A inhibits the expression of PDGFB via YAP1 inactivation 276 
YAP1 has been confirmed to trigger PDGFB transcription by recruiting TEAD1 31. To further 277 
investigate the involvement of YAP1 in linking RASSF1A with PDGFB, we transiently knocked 278 
down YAP1 by using a pool of mixed siRNA in RASSF1A-depleted NPC cells, as confirmed by 279 
western blot analysis (Fig.5A), and downregulated CTGF and CYR61, a hallmark of YAP1 280 
activation as confirmed by qRT-PCR (Fig.5B). Reduced expression of PDGFB and secretion of 281 
PDGF-BB in conditioned medium (CM) were found in YAP1-silenced RASSF1A-depleted 282 
CNE-1 cells compared with control RASSF1A-depleted CNE-1 cells (Fig.5B and 5C) suggesting 283 
that YAP1 mediated the regulatory effect of RASSF1A on PDGFB expression. However, we did 284 
not observe any change in actin cytoskeletal rearrangement after YAP1 silencing (Fig.S4), 285 
indicating that cytoskeletal rearrangement might be upstream of YAP1 activation. To rule out the 286 
off-target of mixed siRNA mentioned above, we repeated the experiments with a single siRNA 287 
that has been reported10. We also observed transient knockdown of YAP1reduced PDGF-BB 288 
secretion and sphere formation (Fig.S5). Furthermore, human recombinant PDGF-BB protein was 289 
added to YAP1-silenced RASSF1A-depleted CNE-1 cells and resulted in increased sphere 290 
formation (Fig.5D and 5E) and also increased migratory and invasive abilities (Fig.5F) compared 291 
with those of IgG-treated RASSF1A-depleted CNE-1 cells. Long time of PDGF-BB treatment led 292 
to a spheroid-forming ability even higher than that of YAP1-expressing cells, possibly because of 293 
a autocrine PDGF-BB/PDGFR positive feedback loop31. Thus, RASSF1A mediated PDGFB 294 
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inhibition via YAP1 inactivation in NPC cells. 295 
3.6 RASSF1A inactivates YAP1 through actin cytoskeletal rearrangement  296 
As indicated above, actin arrangement remained unchanged in response to YAP1 transient 297 
knockdown. In order to substantiate that actin remodeling plays a role in regulating YAP1 298 
activation, we treated RASSF1A-delepted cells with latrunculin b (LTB), an agent that selectively 299 
binds G actin and blocks the formation of F-actin (Fig.6A) and found LTB treatment inhibited 300 
YAP1 nuclear localization (Fig.6B) and prevented YAP1 -regulated gene (CTGF and CYR61) 301 
transcription (Fig.6C) induced by RASSF1A silencing. Reduced expression of PDGFB (Fig.6C) 302 
was also observed in LTB-treated RASSF1A-depleted CNE-1 cells, indicating that actin 303 
cytoskeletal rearrangement acts upstream of YAP1 nuclear import and subsequent activation in 304 
RASSF1A-modulated NPC cells. 305 
4. Discussion 306 
The release of pro- and anti-inflammatory cytokines has a significant role in the triggering of 307 
malignant transformation and display of stem cell properties 32-34 Gene profiling has yielded 308 
important mechanistic insights into the role of PDGFB signaling in RASSF1A-mediated stem cell 309 
plasticity. The PDGFB protein encoded by the PDGFB gene in humans is a member of the 310 
platelet-derived growth factor family that can be released into the microenvironment as a 311 
homodimer (PDGF-BB) or as a heterodimer with the platelet-derived growth factor alpha 312 
(PDGFA) polypeptide (PDGF-AB). Secreted PDGF-BB is involved in cancer progression via 313 
multiple mechanisms. PDGF-BB induces the stem cell phenotype either by accelerating the 314 
maturation of collagen chains through increased LOX activity 35 or by inducing both perivascular 315 
and satellite cell gene expression to acquire improved migration of human hematopoietic cells 36,37. 316 
Our data showed that PDGFB silencing abrogated the RASSF1A depletion-induced malignant 317 
phenotypes of NPC cells. Based on these results, PDGFB or PDGFBB may exhibit a 318 
developmental interest of a new therapeutic target in patients with late-stage malignant NPC. 319 
RASSF1A acts as a natural barrier of stem cell self-renewal by allowing the quaternary 320 
association of YAP1-TEAD with the Oct4 enhancer38. Epigenetic silencing of RASSF1A results in 321 
constitutive nuclear YAP11 accumulation, which increases the extracellular matrix deposition and 322 
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enhances stem-like characteristics39. Consistent with previous studies40,41, our study confirmed 323 
that RASSF1A depletion induced YAP1 nuclear translocation and triggered the expression of its 324 
target genes. Nuclear YAP1 is believed to activate TEAD transcriptional activity and induce the 325 
expression of a broad range of cytokines42. The level of YAP1 in human liver tissues is positively 326 
correlated with the expression of pro-inflammatory cytokines (including MCP-1, TNF-α and IL-6) 327 
43. Enhanced secretion of IL-6 by YAP1-activated hepatocellular carcinoma cells might induce 328 
tumor-associated macrophage maturation, and disruption of YAP1 function could suppress 329 
macrophage chemotaxis and migration44. Recently, YAP1 was reported to trigger PDGFB 330 
transcription by recruiting TEAD1 in bladder cancer cells, as PDGFB has a TEAD-binding motif 331 
in the gene promoter31. PDGFB expression was enhanced after over-expression of YAP1, whereas 332 
activated YAP1 downregulated the expression of IL-1α/β, consistent with our findings (data not 333 
shown)45. We also performed a rescue assay in RASSF1A-depleted NPC cells with transient 334 
knockdown of YAP1 and demonstrated that ectopic PDGF-BB treatment restored the inhibition of 335 
YAP1 knockdown-mediated malignant phenotypes, confirming that PDGFB is directly 336 
downstream of the RASSF1A/YAP1 axis. 337 
YAP1 is regulated by mechanical cues via the interaction of Hippo pathway components with 338 
the cytoskeleton. Cell detachment activates Lats1/2 and leads to YAP1 inhibition through 339 
cytoskeletal reorganization, whereas detachment-induced YAP1 inactivation is required for anoikis 340 
in nontransformed cells46. The small GTPase Rho controls YAP1 nuclear localization by 341 
promoting the formation of actin bundles and stress fibers47. Simultaneously, YAP1 activation also 342 
creates a positive feedback loop to control cytoskeletal remodeling, in turn controlling EMT and 343 
cell metastasis. YAP1 activates the transcription of ARHGAP29 to suppress RhoA activity, 344 
resulting in metastasis promotion48. Our study analysis showed RASSF1A triggered F-actin 345 
rearrangement and subsequent YAP1 nuclear translocation. Knockdown of YAP1 had little effect 346 
on F-actin rearrangement, suggesting that actin remodeling acts as an upstream regulator of YAP1 347 
activity in RASSF1A-mediated biological functions in NPC cells. 348 
Polymerization and depolymerization of actin filaments is a dynamic process controlled by 349 
various regulatory proteins, including Rho family GTPases 49. RASSF1A localizes mainly in the 350 
cytoplasm but can be recruited to the plasma membrane by activated RAS1. Ras signaling 351 
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stimulates pathways toward the Rho GTPase family (RhoA/B/C, Rac, and Cdc42) activation. 352 
Indeed, Rac1 activation is increased in RASSF1A-knockdown cells 50, and direct interaction of 353 
RASSF1A with RhoA suppresses the transforming activity of RhoA51. However we did not 354 
observed change of activity of Rac1 or RhoA in our cell model. Dubois et al. has reported 355 
RASSF1A controls PP2A/GEFH1/RhoB regulation of cofilin-regulated F-actin polymerization10 . 356 
The mechanism by which RASSF1A triggers actin remodeling process in NPC cells needs further 357 
investigation. 358 
In conclusion, the present study indicates that downregulation of RASSF1A is extensively 359 
involved in the acquisition of stem-like characteristics and the motility and invasive phenotypes of 360 
NPC cells. Mechanistically, RASSF1A leads to YAP11 inactivation by remodeling F-actin 361 
assembly and subsequently inhibits the transcriptional activity of PDGFB, an important target 362 
required for sustaining the malignant phenotypes of NPC cells. 363 
Acknowledgments 364 
This work was supported by grants from Natural Science Foundation of Guangdong Province (No. 365 
2020A1515010208), National Natural Science Functional of China (No. 81773354, 81972619, 366 
81672874) and the Innovative Academic Team of Guangzhou Education System (1201610014). 367 
Conflicts of Interest 368 
No potential conflicts of interest were disclosed. 369 
References 370 
1. Donninger, H., Vos, M.D. & Clark, G.J. The RASSF1A tumor suppressor. Journal of cell science 371 
120, 3163-3172 (2007). 372 
2. Dubois, F., Bergot, E., Zalcman, G. & Levallet, G. RASSF1A, puppeteer of cellular homeostasis, 373 
fights tumorigenesis, and metastasis-an updated review. Cell death & disease 10, 928 (2019). 374 
3. Dittfeld, C., Richter, A.M., Steinmann, K., Klagge-Ulonska, A. & Dammann, R.H. The SARAH 375 
Domain of RASSF1A and Its Tumor Suppressor Function. Molecular biology international 2012, 376 
196715 (2012). 377 
4. van der Weyden, L. & Adams, D.J. The Ras-association domain family (RASSF) members and 378 
their role in human tumourigenesis. Biochimica et biophysica acta 1776, 58-85 (2007). 379 
5. Fausti, F., Di Agostino, S., Sacconi, A., Strano, S. & Blandino, G. Hippo and rassf1a Pathways: A 380 
Growing Affair. Molecular biology international 2012, 307628 (2012). 381 
6. Hergovich, A. Mammalian Hippo signalling: a kinase network regulated by protein-protein 382 
interactions. Biochemical Society transactions 40, 124-128 (2012). 383 
7. Hwang, E., et al. Structural insight into dimeric interaction of the SARAH domains from Mst1 384 
14 
 
and RASSF family proteins in the apoptosis pathway. Proceedings of the National Academy of 385 
Sciences of the United States of America 104, 9236-9241 (2007). 386 
8. Bitra, A., Sistla, S., Mariam, J., Malvi, H. & Anand, R. Rassf Proteins as Modulators of Mst1 387 
Kinase Activity. Scientific reports 7, 45020 (2017). 388 
9. Thompson, B.J. YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy. 389 
BioEssays : news and reviews in molecular, cellular and developmental biology 42, e1900162 390 
(2020). 391 
10. Dubois, F., et al. RASSF1A Suppresses the Invasion and Metastatic Potential of Human 392 
Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB 393 
Pathway. Cancer research 76, 1627-1640 (2016). 394 
11. Ahn, E.Y., Kim, J.S., Kim, G.J. & Park, Y.N. RASSF1A-mediated regulation of AREG via the Hippo 395 
pathway in hepatocellular carcinoma. Molecular cancer research : MCR 11, 748-758 (2013). 396 
12. Moroishi, T., Hansen, C.G. & Guan, K.L. The emerging roles of YAP and TAZ in cancer. Nature 397 
reviews. Cancer 15, 73-79 (2015). 398 
13. Lian, I., et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and 399 
differentiation. Genes & development 24, 1106-1118 (2010). 400 
14. Zhu, C., Li, L. & Zhao, B. The regulation and function of YAP transcription co-activator. Acta 401 
biochimica et biophysica Sinica 47, 16-28 (2015). 402 
15. Chang, E.T. & Adami, H.O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer 403 
epidemiology, biomarkers & prevention : a publication of the American Association for Cancer 404 
Research, cosponsored by the American Society of Preventive Oncology 15, 1765-1777 (2006). 405 
16. Chen, Y.P., et al. Nasopharyngeal carcinoma. Lancet 394, 64-80 (2019). 406 
17. Yu, Z., Pestell, T.G., Lisanti, M.P. & Pestell, R.G. Cancer stem cells. The international journal of 407 
biochemistry & cell biology 44, 2144-2151 (2012). 408 
18. Wei, P., et al. Cancer stem-like cell: a novel target for nasopharyngeal carcinoma therapy. 409 
Stem cell research & therapy 5, 44 (2014). 410 
19. Wang, S., et al. Inflammation-Related DNA Damage and Cancer Stem Cell Markers in 411 
Nasopharyngeal Carcinoma. Mediators of inflammation 2016, 9343460 (2016). 412 
20. Li, S., et al. Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal 413 
carcinoma cells. Cell cycle 16, 1601-1610 (2017). 414 
21. He, J., et al. Positive regulation of TAZ expression by EBV-LMP1 contributes to cell 415 
proliferation and epithelial-mesenchymal transition in nasopharyngeal carcinoma. 416 
Oncotarget 8, 52333-52344 (2017). 417 
22. Lo, K.W., et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal 418 
carcinoma. Cancer research 61, 3877-3881 (2001). 419 
23. Chow, L.S., et al. Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. 420 
Oncogene 25, 310-316 (2006). 421 
24. Chow, L.S., et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal 422 
carcinoma. International journal of cancer 109, 839-847 (2004). 423 
25. Ye, M., Huang, T., Ni, C., Yang, P. & Chen, S. Diagnostic Capacity of RASSF1A Promoter 424 
Methylation as a Biomarker in Tissue, Brushing, and Blood Samples of Nasopharyngeal 425 
Carcinoma. EBioMedicine 18, 32-40 (2017). 426 
26. Wu, K., et al. RASSF1A gene methylation is associated with nasopharyngeal carcinoma risk in 427 
Chinese. Asian Pacific journal of cancer prevention : APJCP 16, 2283-2287 (2015). 428 
15 
 
27. Liang, Y.Y., et al. RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis 429 
through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma. Cell cycle 13, 430 
1440-1449 (2014). 431 
28. Liang, Y.Y., et al. RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the 432 
anti-tumor effects of sorafenib in renal cell carcinoma. Cancer letters 432, 75-83 (2018). 433 
29. Hao, D., et al. Evaluation of E-cadherin, beta-catenin and vimentin protein expression using 434 
quantitative immunohistochemistry in nasopharyngeal carcinoma patients. Clinical and 435 
investigative medicine. Medecine clinique et experimentale 37, E320-330 (2014). 436 
30. Nijkamp, M.M., et al. Expression of E-cadherin and vimentin correlates with metastasis 437 
formation in head and neck squamous cell carcinoma patients. Radiotherapy and oncology : 438 
journal of the European Society for Therapeutic Radiology and Oncology 99, 344-348 (2011). 439 
31. Wang, K.J., et al. Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the 440 
Progression and Chemotherapy Resistance of Bladder Cancer. Clinical cancer research : an 441 
official journal of the American Association for Cancer Research 25, 1070-1086 (2019). 442 
32. Korkaya, H., Liu, S. & Wicha, M.S. Regulation of cancer stem cells by cytokine networks: 443 
attacking cancer's inflammatory roots. Clinical cancer research : an official journal of the 444 
American Association for Cancer Research 17, 6125-6129 (2011). 445 
33. Jiang, L., et al. Overexpression of PIMREG promotes breast cancer aggressiveness via 446 
constitutive activation of NF-kappaB signaling. EBioMedicine (2019). 447 
34. Ren, L., et al. MiR-454-3p-Mediated Wnt/beta-catenin Signaling Antagonists Suppression 448 
Promotes Breast Cancer Metastasis. Theranostics 9, 449-465 (2019). 449 
35. Mihaylova, Z., et al. Role of PDGF-BB in proliferation, differentiation and maintaining stem 450 
cell properties of PDL cells in vitro. Archives of oral biology 85, 1-9 (2018). 451 
36. Yin, X., et al. PDGFB-expressing mesenchymal stem cells improve human hematopoietic stem 452 
cell engraftment in immunodeficient mice. Bone marrow transplantation (2019). 453 
37. Gerli, M.F.M., et al. Combined Notch and PDGF Signaling Enhances Migration and Expression 454 
of Stem Cell Markers while Inducing Perivascular Cell Features in Muscle Satellite Cells. Stem 455 
cell reports 12, 461-473 (2019). 456 
38. Papaspyropoulos, A., et al. RASSF1A uncouples Wnt from Hippo signalling and promotes YAP 457 
mediated differentiation via p73. Nature communications 9, 424 (2018). 458 
39. Pankova, D., et al. RASSF1A controls tissue stiffness and cancer stem-like cells in lung 459 
adenocarcinoma. The EMBO journal 38, e100532 (2019). 460 
40. Keller, M., et al. NDR2 kinase contributes to cell invasion and cytokinesis defects induced by 461 
the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells. Journal of 462 
experimental & clinical cancer research : CR 38, 158 (2019). 463 
41. Pefani, D.E., et al. TGF-beta Targets the Hippo Pathway Scaffold RASSF1A to Facilitate 464 
YAP/SMAD2 Nuclear Translocation. Molecular cell 63, 156-166 (2016). 465 
42. Lin, K.C., Park, H.W. & Guan, K.L. Regulation of the Hippo Pathway Transcription Factor TEAD. 466 
Trends in biochemical sciences 42, 862-872 (2017). 467 
43. Song, K., et al. YAP in Kupffer cells enhances the production of pro-inflammatory cytokines 468 
and promotes the development of non-alcoholic steatohepatitis. Hepatology (2019). 469 
44. Zhou, T.Y., et al. Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits 470 
tumor-associated macrophages. Journal of pharmacological sciences 138, 89-95 (2018). 471 
45. Hao, Y., Chun, A., Cheung, K., Rashidi, B. & Yang, X. Tumor suppressor LATS1 is a negative 472 
16 
 
regulator of oncogene YAP. The Journal of biological chemistry 283, 5496-5509 (2008). 473 
46. Zhao, B., et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization 474 
to induce anoikis. Genes & development 26, 54-68 (2012). 475 
47. McBeath, R., Pirone, D.M., Nelson, C.M., Bhadriraju, K. & Chen, C.S. Cell shape, cytoskeletal 476 
tension, and RhoA regulate stem cell lineage commitment. Developmental cell 6, 483-495 477 
(2004). 478 
48. Qiao, Y., et al. YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis. 479 
Cell reports 19, 1495-1502 (2017). 480 
49. Sit, S.T. & Manser, E. Rho GTPases and their role in organizing the actin cytoskeleton. Journal 481 
of cell science 124, 679-683 (2011). 482 
50. Dallol, A., et al. Involvement of the RASSF1A tumor suppressor gene in controlling cell 483 
migration. Cancer research 65, 7653-7659 (2005). 484 
51. Lee, M.G., et al. RASSF1A Directly Antagonizes RhoA Activity through the Assembly of a 485 
Smurf1-Mediated Destruction Complex to Suppress Tumorigenesis. Cancer research 76, 486 
1847-1859 (2016). 487 
Figure Legends 488 
Figure 1 Expression of RASSF1A correlates with the self-renewal properties and tumorigenicity 489 
of NPC cells. 490 
(A) Protein expression levels of RASSF1A in NPC cells; β-actin was used as the loading control. (B, C, D) CNE-2 491 
cells stably transfected with overexpressing RASSF1A (RF1) or with empty vector (Vec) were analyzedas follows. 492 
(B, left panel) RASSF1A protein expression levels were determined by western blot analysis; β-actin was used as 493 
theloading control. (C) A cell proliferation curve was constructed from MTS assay results, the data are presented 494 
as the mean± S.D. values, **p < 0.01, Student’s t-test. (D)Single-cell suspensions were seeded in 495 
ultra-low-attachment culture plates. The formed spheroids were counted via microscopy, and representative 496 
images are shown. The representative images and numbers of RASSF1A-overexpressing and control cells were 497 
compared, *p < 0.05, Student’s t-test. Scale bar: 200µm. (B, E, F) CNE-1 cells stably transfected with shRNA 498 
targeting RASSF1A (sh2, sh5) or scrambled shRNA (shLuc) were analyzedas follows. (B, right panel) Western 499 
blot analysis of RASSF1A expression; β-actin was used as the loading control. (E) A cell proliferation curve was 500 
constructed from MTS assay results, the data are presented as the mean± S.D. values, *p< 0.05 and ** p< 0.01 for 501 
CNE-1/sh2 cells compared with CNE-1/shLuc cells; ## p<0.01 for CNE-1/sh5 cells compared with CNE-1/shLuc 502 
cells; Student’s t-test.). (F) Single-cell suspensions were seeded in ultra-low-attachment culture plates. The formed 503 
spheroids were counted via microscopy, and representative images of CNE-1 cells transfected with RASSF1A 504 
shRNAs or negative control scrambled shRNA are shown. (G) A total of 2×105 (upper) and 5×104 (lower) 505 
RASSF1A-overexpressing and its control CNE-2 cells were subcutaneously injected into NOD/SCID mice (n=10 506 
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mice/group). Summary of tumorigenicity in mice were shown. The TIF and p value were calculated using ELDA 507 
software. (H) A total of 2×105 (upper) and 5×104 (lower) RASSF1A shRNA- or scrambled shRNA-targeting 508 
CNE-1 cells were subcutaneously injected into NOD/SCID mice (n=10 mice/group). Summary of tumorigenicity 509 
in mice were shown. The TIF and p value were calculated using ELDA software.  510 
Figure 2 RASSF1A regulated expression of molecules involved in cell movement and ultimately 511 
inhibits the motility and invasive phenotype of NPC cells. 512 
(A)Western blot analysis of E-cadherin and vimentin in RASSF1A-overexpressing (left panel) CNE-2 cells, 513 
RASSF1A-depleted (right panel) CNE-1 cells and their corresponding control cells, GAPDH was used as the 514 
loading control. (B) RASSF1A markedly attenuated the migration and invasion characteristics of CNE-2cells with 515 
or without presence of mitomycin C(1ug/ml) . Representative images of the migration assay (upper) and invasion 516 
assay (lower) of RASSF1A-overexpressing and control CNE-2 cells. The data are presented as the mean± S.D. 517 
values, ** p< 0.01, Student’s t-test. Photomicrographs were acquired at 40× magnification. (C) RASSF1A 518 
depletion enhanced CNE-1 cell migration and invasion with or without presence of mitomycin C(1ug/ml), as 519 
determined by migration (upper pannels) and invasion (lower pannels) assays, the data are presented as the mean± 520 
S.D. values, **p< 0.01, Student’s t-test. Photomicrographs were acquired at 40× magnification. 521 
Figure 3 PDGFB is crucial for maintaining malignant properties induced by RASSF1A in NPC 522 
cells. 523 
(A) A heat map generated using the significantly changed genes categorized in the “cytokine-cytokine receptor 524 
interaction pathway” is shown. (B, C) mRNA expression (B) was evaluated by qRT-PCR and protein 525 
concentration by ELISA (C) in CM of RASSF1A-overexpressing CNE-2 cells, RASSF1A-depleted CNE-1 cells 526 
and their corresponding control cells, The data are presented as the mean± S.D. values, **p < 0.01, Student’s t-test. 527 
(D, E, F, G) PDGFB was transiently knocked down with a pool of siRNA or treated with a neutralizing antibody 528 
for PDGF-BB (10µg/mL) in RASSF1A-depleted CNE-1 cells. PDGF-BB secretion in the CM was measured by 529 
ELISA (D), **p < 0.01, Student’s t-test. (E) Number of spheroids formed was determined via microscopy, and 530 
representative images (E left panel) are shown. The formed spheroids were compared (E right panel), the data are 531 
presented as the mean± S.D. values, *p < 0.05, **p < 0.01, Student’s t-test; ns: non-sinificant. Scale bar: 200µm. 532 
Representative images of the migration assay (F) and invasion assay (G) are shown, the data are presented as the 533 
mean± S.D. values, **p < 0.01, Student’s t-test. (H, I, J) Recombinant PDGF-BB or IgG was added to 534 
RASSF1A-overexpressing CNE-2 cells. Representative images of sphere formation (H), migration (I) and invasion 535 
(J) assays of RASSF1A-overexpressing CNE-2 cells treated with PDGF-BB (the culture medium was 536 
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supplemented with 20 ng/ml or an equal volume of control IgG) are shown, The data are presented as the mean± 537 
S.D. values,*p < 0.05, **p < 0.01, Student’s t-test. Scale bar: 200µm. 538 
Figure 4 RASSF1A induces actin cytoskeletal rearrangement and inhibits YAP1 activation. 539 
(A) Representative images of F-actin stained with phalloidin and observed by immunofluorescence microscopy. 540 
Nuclei were visualized by DAPI staining, scale bar: 25µm. (B) YAP1 expression in the total, cytosolic or nuclear 541 
fractions of RASSF1A-overexpressing CNE-2 cells, RASSF1A-delepted CNE-1 cells and their corresponding 542 
control cells were determined by western blot analysis. (C) mRNA quantification of CYR61 and CTGF by using 543 
qRT-PCR; GAPDH was used as the internal control. The data are presented as the mean± S.D. values, *p < 0.05, 544 
**p < 0.01, Student’s t-test. 545 
Figure 5 PDGFB induction by YAP1 mediates the modulatory effect of RASSF1A on the 546 
malignant phenotypes of NPC cells. 547 
(A, B, C) YAP1 was transiently knocked down in RASSF1A-depleted CNE-1 cells. (A)In the indicated cells, 548 
YAP1 protein expression was assessed by using western blotting; (B) PDGFB, CYP61 and CTGF mRNA 549 
expression was assessed by qRT-PCR; (C) Concentration of PDGF-BB secreted in CM was measured by ELISA. 550 
The data are presented as the mean± S.D. values, *p < 0.05, **p < 0.01, Student’s t-test.  (D, E, F) Recombinant 551 
PDGF-BB or IgG was added to YAP1-silenced NPC cells. (D) The formed spheroids were counted via microscopy, 552 
and (E) representative images are shown. (F) The impact of PDGF-BB treatment on the migration and invasion of 553 
RASSF1A-depleted cells was determined by Transwell assays. The data are presented as the mean± S.D. values, 554 
*p < 0.05, **p < 0.01, Student’s t-test. Scale bar: 200µm. 555 
Figure 6 RASSF1A inactivates YAP1 through actin rearrangement. 556 
(A, B, C) RASSF1A-depleted CNE-1 cells were treated with or without LTB (10µM) treatment for 1 hour, and its 557 
control CNE-1 cells were also included into assays as follows. (A) Representative images of F-actin stained with 558 
phalloidin were observed by immunofluorescence microscopy. Nuclei were visualized by DAPI staining, scale bar: 559 
25µm. (B) YAP1 expression in the total, cytosolic or nuclear fractions was determined by western blot analysis. (C) 560 
mRNA quantification of YAP1, CYR61,CTGF and PDGFB by using qRT-PCR; GAPDH was used as the internal 561 
control. The data are presented as the mean± S.D. values, **p < 0.01, Student’s t-test. 562 






